Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2013

View Archived Issues

ASP-1017FM has potentially beneficial effects on migraine

Hanmi Science discloses new protein kinase inhibitors for cancer

Pulmatrix commences phase Ib COPD study

Novel agents for metabolic diseases disclosed by Cadila Healthcare

Genmab submits IND to conduct phase I study of HuMax-TF-ADC

Gilead Sciences presents novel agents for HIV infection

Researchers at Rutgers disclose new antibacterial RNA polymerase inhibitors

Daiichi Sankyo and Ube Industries synthesize new CETP inhibitors

Experiments profile preclinical activity of Alzheimer's disease candidate AZD-3293

Novel drug and drug target for the treatment of addictive disorders characterized

Noven Pharmaceuticals reports topline results from phase II d-ATS

Results of a phase I evaluation of antigen-specific tolerance for multiple sclerosis

Ligand signs license agreement with Azure Biotech for lasofoxifene

New biomaterial coatings to improve bone-bioimplant interface stability

Cellular Biomedicine begins phase I trial of adipose-derived mesenchymal progenitor cells

Johnson & Johnson reviews second quarter 2013

Aquinox begins dosing in phase II trial of AQX-1125 in BPS/IC

Protalex continues enrollment in phase Ib trial of PRTX-100 following third interim review

Mast Therapeutics' QT study of MST-188 meets primary endpoint

Charleston Laboratories completes pre-IND meeting regarding migraine treatment

Phase III trial comparing obinutuzumab to Rituxan in CLL meets primary endpoint

Arrowhead commences phase I trial of RNAi therapeutic

Quest PharmaTech and AD Biotech form joint venture

Trovagene's reports validation of assay for detecting BRAF mutation in urine

Roche launches new drug monitoring tests for immunosuppressive therapies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...